XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Fair Value of Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of Notional Amounts of Outstanding Derivative Positions
The following table presents the notional contract amounts for forward contracts outstanding:

As of
FASB ASC Topic 815 DesignationJune 30, 2024December 31, 2023
Forward exchange contractsCash flow hedge$228,171 $223,839 
Forward exchange contractsNon-designated53,524 55,789 
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)
Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) ("AOCI") and net earnings on our consolidated condensed statements of comprehensive income and our consolidated condensed balance sheets:

Amount of Gain (Loss) Recognized in AOCI
Consolidated Condensed Statements of Comprehensive Income
Amount of Gain Reclassified from AOCI
Three Months Ended June 30,
Total Amount of Line Item Presented
Derivative Instrument20242023Location of amount reclassified2024202320242023
Foreign exchange contracts$(499)$2,753 Net Sales$332,097 $317,652 $1,349 $915 
 Cost of Sales148,368 146,962 626 1,175 
Pre-tax gain (loss)
$(499)$2,753 $1,975 $2,090 
Tax expense (benefit)
(121)667 479 507 
Net gain (loss)
$(378)$2,086 $1,496 $1,583 

Amount of Gain Recognized in AOCI
Consolidated Condensed Statements of Comprehensive Income
Amount of Gain Reclassified from AOCI
Six Months Ended June 30,
Total Amount of Line Item Presented
Derivative Instrument20242023Location of amount reclassified2024202320242023
Foreign exchange contracts$6,759 $5,291 Net Sales$644,371 $613,121 $1,990 $1,490 
Cost of Sales288,677 287,110 1,372 1,981 
Pre-tax gain$6,759 $5,291 $3,362 $3,471 
Tax expense1,639 1,281 815 842 
Net gain $5,120 $4,010 $2,547 $2,629 
.
Derivatives Not Designated as Hedging Instruments
Net gains from derivative instruments not accounted for as hedges and losses on our intercompany receivables on our consolidated condensed statements of comprehensive income were:

Three Months Ended June 30,Six Months Ended June 30,
Derivative Instrument
Location on Consolidated Condensed Statements of Comprehensive Income
2024202320242023
  
Net gain on currency forward contracts
Selling and administrative expense$211 $768 $882 $403 
Net loss on currency transaction exposures
Selling and administrative expense$(965)$(1,355)$(2,210)$(1,279)
Schedule of Fair Value for Forward Foreign Exchange Contracts The following tables summarize the fair value for forward foreign exchange contracts outstanding at June 30, 2024 and December 31, 2023:
June 30, 2024Location on Consolidated Condensed Balance SheetAsset Fair ValueLiabilities Fair ValueNet
Fair
Value
Derivatives designated as hedged instruments:   
Foreign exchange contractsPrepaid expenses and other current assets$4,677 $(1,258)$3,419 
Foreign exchange contractsOther assets824 (692)132 
$5,501 $(1,950)$3,551 
Derivatives not designated as hedging instruments:   
Foreign exchange contractsOther current liabilities(214)(207)
Total derivatives$5,508 $(2,164)$3,344 

December 31, 2023Location on Consolidated Condensed Balance SheetAsset Fair ValueLiabilities Fair ValueNet
Fair
Value
Derivatives designated as hedged instruments:  
Foreign exchange contracts Prepaid expenses and other current assets$3,761 $(3,197)$564 
Foreign exchange contractsOther long-term liabilities24 (433)(409)
$3,785 $(3,630)$155 
Derivatives not designated as hedging instruments:  
Foreign exchange contractsOther current liabilities39 (209)(170)
Total derivatives$3,824 $(3,839)$(15)
Fair Value Measurement Inputs and Valuation Techniques The recurring Level 3 fair value measurements of contingent consideration for which the liabilities are recorded include the following significant unobservable inputs as of June 30, 2024:
Assumptions
Unobservable InputIn2BonesBiorez
Discount rate8.28%13.31%
Revenue volatility19.26%22.15%
Projected year of payment
2024-2026
2024-2026
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Changes in the fair value of contingent consideration liabilities for the six months ended June 30, 2024 and 2023 are as follows:
In2BonesBiorez
2024202320242023
Balance as of January 1,$41,393 $70,198 $128,751 $116,234 
Payments
(3,028)— (36,401)— 
Changes in fair value of contingent consideration(20,760)136 5,541 3,663 
Balance as of June 30,$17,605 $70,334 $97,891 $119,897